An Open Label Study Assessing SVR and Viral Resistance Profile With Boceprevir Plus PEG-IFN Plus Ribavirin Triple Therapy in HCV-1 Infected Patients With Insulin Resistance Who Have Failed PEG-IFN Plus Ribavirin Dual Therapy
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 28 Jan 2014 New source identified and integrated (European Clinical Trials Database record; EudraCT2012-002771-33).
- 23 Dec 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by as reported by ClinicalTrials.gov.
- 06 Sep 2013 Planned End Date changed from 1 Sep 2015 to 1 Dec 2015 as reported by as reported by ClinicalTrials.gov.